ReviewExperimental hematology & oncology2026
Crosstalk between ferroptosis and extracellular vesicles in cancer: from interaction to clinical application.
Review in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding the spatiotemporal characteristics of ferroptosis: reshaping tumour therapeutic strategies.Experimental hematology & oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cancer continues to pose a significant issue to public health. Despite the considerable advancements in popular therapies such as surgery, radiation, chemotherapy, targeted therapy, and immunotherapy, a substantial number of patients continue to suffer from cancer due to severe treatment resistance. As a result, it is imperative to have a deeper understanding of the mechanisms behind cancer growth and therapy resistance. Ferroptosis, an iron-dependent form of cell death characterized by excessive lipid peroxidation, has recently been described, attracting heightened interest in its implications in cancer. Ferroptosis offers a new conceptual framework for understanding cancer progression. Some treatments function via regulating ferroptosis, and the tough insensitive to various therapies also involves ferroptosis resistance. Hence, targeting ferroptosis may benefit the cancer treatments. Extracellular vesicles (EVs) are essential mediators in cell-to-cell communications and are significantly impacted by environmental or cellular stress. The relationship between EVs and ferroptosis has recently been steadily demonstrated, and it has also been possible to use EVs to target ferroptosis to treat cancer. We present a novel perspective on cancer by reexamining the existing knowledge of ferroptosis and EVs in this disease. This includes a comprehensive overview of the relationships between ferroptosis and EVs and their therapeutic applications, focusing on contemporary ferroptosis-targeting EVs in the context of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.